Market Research Logo

Global Urological Cancer Market Analysis 2016 - Forecast to 2022

Global Urological Cancer Market Analysis 2016 - Forecast to 2022

Hoovers Research analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present unique and reliable analysis. Assessment of major trends with potential impact on the market during the next five years, including a deep dive analysis of market segmentation which comprises of sub markets, regional and country level analysis. The report provides a comprehensive outlook about the market share along with strategic recommendations based on the emerging segments.

This report analyzes the global markets for "Urological Cancer". The market assessment is performed through standard and the tailored research methodology approach. The market overview offers in depth analysis at the regional and country level, for instance North America (U.S., Canada and Mexico), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, Australia, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America). Annual estimations and forecasts are provided from the year 2013 to 2022 for each given segment and sub segments. Market data derived from the authenticated and reliable sources is subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends. Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, and other activities.

This report provides:

  • Market Sizing estimations and forecasts for a minimum of 6 years of all the given segments, sub segments and the regional markets
  • Identifying market dynamics (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Regional and country level market analysis
  • Competitive landscaping mapping the key common trends
  • Company profiling covering the financials, recent activities and the future strategies
  • Supply chain trends mapping the recent advancements
  • Strategic recommendations for the new entrants


1 Introduction
1.1 Scope of the Report
1.2 Report Description
1.3 Research Methodology
1.4 Research Sources
1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Assumptions
1.5 List of Abbreviations
2 Executive Summary
3 Market Analysis
3.1 Market Segmentation
3.2 Market Size Estimation
3.3 Market Drivers
3.4 Market Constraints
3.5 Pipeline Analysis
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Urological Cancer Market by Product
5.1 Introduction
5.2 Xofigo (radium Ra 223 dichloride)
5.3 Jevtana (cabazitaxel)
5.4 Inlyta (axitinib)
5.5 Votrient (pazopanib hydrochloride)
5.6 Sutent (sunitinib malate)
5.7 Zytiga (abiraterone acetate)
5.8 Xtandi (enzalutamide)
5.9 Opdivo (nivolumab)
5.10 Provenge (sipuleucel-T)
6 Urological Cancer Market by Cancer Type
6.1 Introduction
6.2 Prostate Cancer
6.3 Bladder Cancer
6.4 Kidney Cancer
6.5 Testicular Cancer
7 Urological Cancer Market by Treatment
7.1 Introduction
7.2 Targeted Therapies
7.3 Chemotherapy
7.4 Hormonal Therapies
7.5 Surgery and Radiation Therapy
8 Geographical Segmentation
8.1 North America
8.1.1 US
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 France
8.2.3 Italy
8.2.4 UK
8.2.5 Spain
8.3 Asia Pacific
8.3.1 Japan
8.3.2 China
8.3.3 India
8.3.4 Australia
8.3.5 New Zealand
8.3.6 Rest of Asia Pacific
8.4 RoW
8.4.1 Latin America
8.4.2 Middle East
8.4.3 Africa
8.4.4 Others
9 Vendor Landscaping
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiles
10.1 Novartis
10.1.1 Business Overview
10.1.2 SWOT Analysis
10.1.3 Financial Overview
10.1.4 Strategy
10.1.5 Key Activities
10.2 Pfizer
10.3 Johnson & Johnson
10.4 AstraZeneca
10.5 Astellas
10.6 Bristol-Myers Squibb
10.7 Abbott Laboratories
10.8 Celgene Corporation
10.9 Dendreon Corporation
10.10 Ferring Pharmaceuticals
10.11 GlaxoSmithKline plc
10.12 Indevus Pharmaceuticals Inc
10.13 Ipsen
10.14 Roche Healthcare
10.15 Sanofi S.A.
10.16 Tolmar Inc
11 Appendix
12 Disclaimer
List of Tables
Table 1 Global Urological Cancer Market Analysis, by Region, 2013-2022 ($MN)
Table 2 Global Urological Cancer Market Analysis, by Product Type, 2013-2022 ($MN)
Table 3 Global Xofigo (radium Ra 223 dichloride) Market Analysis, by Region, 2013-2022 ($MN)
Table 4 Global Xofigo (radium Ra 223 dichloride) Market Analysis, by Cancer Type, 2013-2022 ($MN)
Table 5 Global Xofigo (radium Ra 223 dichloride) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 6 Global Jevtana (cabazitaxel) Market Analysis, by Region, 2013-2022 ($MN)
Table 7 Global Jevtana (cabazitaxel) Market Analysis, by Cancer Type, 2013-2022 ($MN)
Table 8 Global Jevtana (cabazitaxel) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 9 Global Inlyta (axitinib) Market Analysis, by Region, 2013-2022 ($MN)
Table 10 Global Inlyta (axitinib) Market Analysis, by Cancer Type, 2013-2022 ($MN)
Table 11 Global Inlyta (axitinib) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 12 Global Votrient (pazopanib hydrochloride) Market Analysis, by Region, 2013-2022 ($MN)
Table 13 Global Votrient (pazopanib hydrochloride) Market Analysis, by Cancer Type 2013-2022 ($MN)
Table 14 Global Votrient (pazopanib hydrochloride) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 15 Global Sutent (sunitinib malate) Market Analysis, by Region, 2013-2022 ($MN)
Table 16 Global Sutent (sunitinib malate) Market Analysis, by Cancer Type 2013-2022 ($MN)
Table 17 Global Sutent (sunitinib malate) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 18 Global Zytiga (abiraterone acetate) Market Analysis, by Region, 2013-2022 ($MN)
Table 19 Global Zytiga (abiraterone acetate) Market Analysis, by Cancer Type 2013-2022 ($MN)
Table 20 Global Zytiga (abiraterone acetate) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 21 Global Xtandi (enzalutamide) Market Analysis, by Region, 2013-2022 ($MN)
Table 22 Global Xtandi (enzalutamide) Market Analysis, by Cancer Type 2013-2022 ($MN)
Table 23 Global Xtandi (enzalutamide) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 24 Global Opdivo (nivolumab) - Bristol-Myers Squibb Market Analysis, by Region, 2013-2022 ($MN)
Table 25 Global Opdivo (nivolumab) - Bristol-Myers Squibb Market Analysis, by Cancer Type 2013-2022 ($MN)
Table 26 Global Opdivo (nivolumab) - Bristol-Myers Squibb Market Analysis, by Treatment, 2013-2022 ($MN)
Table 27 Global Provenge (sipuleucel-T) Market Analysis, by Region, 2013-2022 ($MN)
Table 28 Global Provenge (sipuleucel-T) Market Analysis, by Cancer Type 2013-2022 ($MN)
Table 29 Global Provenge (sipuleucel-T) Market Analysis, by Treatment, 2013-2022 ($MN)
Table 30 Global Urological Cancer Market Analysis, by Cancer Type, 2013-2022 ($MN)
Table 31 Global Prostate Cancer Market Analysis, by Region, 2013-2022 ($MN)
Table 32 Global Prostate Cancer Market Analysis, by Treatment, 2013-2022 ($MN)
Table 33 Global Prostate Cancer Market Analysis, by Product, 2013-2022 ($MN)
Table 34 Global Bladder Cancer Market Analysis, by Region, 2013-2022 ($MN)
Table 35 Global Bladder Cancer Market Analysis, by Treatment, 2013-2022 ($MN)
Table 36 Global Bladder Cancer Market Analysis, by Product, 2013-2022 ($MN)
Table 37 Global Kidney Cancer Market Analysis, by Region, 2013-2022 ($MN)
Table 38 Global Kidney Cancer Market Analysis, by Treatment, 2013-2022 ($MN)
Table 39 Global Kidney Cancer Market Analysis, by Product, 2013-2022 ($MN)
Table 40 Global Testicular Cancer Market Analysis, by Region, 2013-2022 ($MN)
Table 41 Global Testicular Cancer Market Analysis, by Treatment, 2013-2022 ($MN)
Table 42 Global Testicular Cancer Market Analysis, by Product, 2013-2022 ($MN)
Table 43 Global Urological Cancer Market Analysis, by Treatment, 2013-2022 ($MN)
Table 44 Global Targeted Therapies Market Analysis, by Region, 2013-2022 ($MN)
Table 45 Global Targeted Therapies Market Analysis, by Cancer Type, 2013-2022 ($MN)
Table 46 Global Targeted Therapies Market Analysis, by Product, 2013-2022 ($MN)
Table 47 Global Chemotherapy Market Analysis, by Region, 2013-2022 ($MN)
Table 48 Global Chemotherapy Market Analysis, by Cancer Type, 2013-2022 ($MN)
Table 49 Global Chemotherapy Market Analysis, by Product, 2013-2022 ($MN)
Table 50 Global Hormonal Therapies Market Analysis, by Region, 2013-2022 ($MN)
Table 51 Global Hormonal Therapies Market Analysis, by Cancer Type, 2013-2022 ($MN)
Table 52 Global Hormonal Therapies Market Analysis, by Product, 2013-2022 ($MN)
Table 53 Global Surgery and Radiation Therapy Market Analysis, by Region, 2013-2022 ($MN)
Table 54 Global Surgery and Radiation Therapy Market Analysis, by Cancer Type, 2013-2022 ($MN)
Table 55 Global Surgery and Radiation Therapy Market Analysis, by Product, 2013-2022 ($MN)
Note: Regional tables are presented in the similar manner as the above

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report